1. From: The μ-Opioid Receptor in Cancer Progression:Is There a Direct Effect?
Anesthes. 2012;116(4): doi: /ALN.0b013e31824b9512
Figure Legend:
Fig. 1. Schematic diagram representing the mechanism(s) by which methylnaltrexone inhibits angiogenesis. Vascular endothelial growth factor (VEGF) binding to VEGF receptors induces Src activation, Src-mediated Akt, RhoA, and mammalian target of rapamycin (mTOR) activation and consequent endothelial cell proliferation, migration, and actin cytoskeletal reorganization required for angiogenesis. Methylnaltrexone (MNTX) inhibits the μ-opioid receptor (MOR) and promotes tyrosine phosphatase activity, leading to Src inactivation. This promotes Akt, RhoA, and mTOR inactivation and consequent inhibition of angiogenesis.
Date of download: 10/16/2017
Copyright © 2017 American Society of Anesthesiologists. All rights reserved.